Our quantitative assessment considered neocortical p-tau pathologies in 22 cases withvarying exposures to TBI and known CTE-NC spanning ‘low’- and ‘high’-stage pathology.Furthermore, we compared these pathologies with those observed in material from patientswith clinically diagnosed Alzheimer’s disease and confirmed Alzheimer’s diseaseneuropathologic changes. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.